retatrutide side effects phase 2 trial VisualAbstract: reduces body weight by 17.5% in patients with obesity An experimental weight-loss drug from

Clinical evidence suggests that retatrutide achieves durable weight loss, which is crucial for lasting health gains

MIDI Health started with three in August 2025 (which was oh, so predictable), and now they have five, and yes, I will be reviewing a couple of them

Join our Polaris Insiders program to get rewarded for loyalty with exclusive deals, news about upcoming products, and more

In light of the robust correlations observed among MASLD, T2DM, and obesity, semaglutide, an approved GLP-1R agonist for treating T2DM and obesity, exhibited a significant reduction in liver fat content (LFC) and visceral adipose tissue (VAT) volumes [12]